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1. IX, +roduction 
In the central nervous ystem, opiates produce their 
various pharmacological effects primarily by interact- 
ing with stereospecific binding sites [l-3]. These sites 
are presumably carried by membrane-bound opiate 
receptors which, as such, have not yet been unambig 
ously identified and, a fortiori, purified. 
A first step toward these major goals is to prove 
that macromolecular (?) species which bind opiates 
with high affmity and stereospecifically do exhibit 
well defined hydrodynamic properties in solution. A 
classical approach [4] makes use of highly selective, 
nearly irreversible radioactive ligands to label the 
receptor molecule(s). The resulting membrane-bound, 
radioactive complex is then solubilized with the ap- 
propriate chaotropic agent after which its hydrody- 
namic properties are analyzed by conventional tech- 
niques, namely gel filtration and ultracentrifugation 
[Sl. 
Here, following [6], we have selected [3H]etorphine 
as the specific radioactive probe but a solubihzing 
agent different from Brij 36 T:sodium cholate, an 
anionic detergent. We show that a crude membrane 
fraction from the rat brain contains a component of 
high M; which, in solution, exhibits welldefined 
although unusual hydrodynamic properties. Given 
our experimental protocol, this component may repre- 
sent an opiate receptor. However, the possibility that 
there exist, in addition to this particular entity, other 
lower Mr species with similar binding characteristics, 
is discussed. 
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2. Materials and methods 
2. I. Prepara tiun of the crude membrane fraction 
(CMF) from rat brain 
Adult Wistar ats were killed by decapitation. The 
brains (minus the cerebellum) were rapidly dissected 
out and homogenized at.4OC in a total volume (v,) 
of 12 ml/g wet tissue of 0.32 M sucrose in Tris-HCl 
(1 mM , pH 7.4). Homogenization was completed in 
a Potter-Elvehjem tissue grinder by 10 strokes of the 
teflon pestle, motor driven at 800-1000 rev./mm. 
The result~g suspension was incubated for 30 min at 
35°C and centrifuged (0-2°C) in a Beckman rotor 
type 30 for 30 min at 30 000 rev./min. The pellet was 
dispersed (PoIytron)in a large excess of ice-cold Tris- 
HCl(50 mM, pH 7.4) (from now on referred to as 
‘buffer’) and centrifuged as before. The washed pellet 
was homogenized (Polytron) in v,/2 of buffer to 
yield the CMF (12-l 4 mg protein/ml). 
2.2. Labelling of the CMF with [3H]etorphine 
This was carried out routinely by incubating for 
20 min at 35’C the following mixture: 4.0 ml CMF, 
I .O ml buffer (with and without 20 PM levo~hanol) 
and 5.0 ml 4 nM [3H]etorphine (41.4 Cilmmol, the 
Radiochemical Center, Amersham), in buffer. After 
incubation, the reaction mixture was chilled down to 
0°C centrifuged and washed as above. The final pellet 
was dispersed (Polytron) in 5.0 ml ice-cold buffer to 
give the [3H]CMF (10-l 1 mg protein/ml). 
2.3. Solubilization of the(3H]CMF with sodium 
cholate 
To 2.4 ml [3H]CMF were added 0.3 ml of ice-cold 
buffer and 0.3 ml of Na-cholate at the desired con- 
centration (usually 1 O%, w/v, in buffer). After 15 min 
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at O”C, the mixture was centrifuged in the cold, in a 
Beckman rotor type 30 for 30 min at 30 000 rev./min. 
The supernatant (2 mg protein/ml) constituted the 
radioactive cholate extract. 
2.4. Gel filtration 
Sepharose 6B (Pharmacia, 83 ml) was packed into 
a glass column of 1.5 by 45 cm and fully equilibrated 
at cold-room temperature with Nacholate (l%, w/v) 
in Tris-HCl(50 mM, pH 7.4). The column was cali- 
brated with a Pharmacia HMW kit (blue dextran 2000, 
thyroglobulin, ferritin, catalase, aldolase), cytochrome 
c (Merck) and [3H]etorphine. An aliquot (0.5 ml) of 
the radioactive detergent extract was applied and 
eluted at a constant flow rate (Mariotte flask) of -13 
ml/h. Fractions of 1 .O ml were collected and 0.4 ml 
each fraction was mixed with 6 ml home-made scin- 
tillation liquid (toluene 0.7 1:Triton N-101 0.3 
1 :butylPBD 7 g) and counted in an Intertechnique 
model SL-30 counter. 
2 5. Density gradient ultracen trifugation 
Density gradients in Na-cholate (l%, w/v)-Tris- 
HCl(50 mM, pH 7.4) were prepared in the appropriate 
centrifuge tubes with a conventional gradient maker. 
They consisted of 5 ml sucrose (Merck) 5-20% (w/v). 
An aliquot (0.15 ml) of the radioactive detergent ex- 
tract was layered on top of the gradient and spun at 
0-2°C in a Beckman rotor type SW 65 for 4 h at 
64 000 rev./mm. The gradients were ‘calibrated’ with 
a mixture of aldolase and catalase from the Pharmacia 
HMW kit. Fractions of 5 drops were collected auto- 
matically (peristaltic pump) by a LKB piercing unit 
connected to an Isco fraction collector. The radioactiv- 
ity of each fraction was counted as above. 
2.6. Protein assay 
Protein concentrations were estimated as in [7] 
with bovine serum albumin as standard. 
3. Results 
3 .l . Labelling of the CMF with /3Hletolphine and 
solubilization of the r3HJetorphine labelled CMF 
by sodium cholate 
Under the labelling conditions in section 2,80-90% 
of the bound radioactivity was levorphanol-‘displace- 
able’; i.e., non-specific binding amounted to only 
lo-20% of total binding. The optimal solubilizing 
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Fig.1. Solubilization of the radioactivity specifically bound 
to a rat brain CMF by increasing concentrations of Na-cholate. 
concentration of Nacholate was determined by incu- 
bating (15 min, 0°C) the [3H]CMF with increasing 
amounts of detergent. Fig.1 demonstrates that Na- 
cholate is a very efficient solubilizing agent over 0.5- 
1% (w/v). It is especially important to note that at 
1% (w/v) of Nacholate, solubilization of the mem- 
brane-bound radioactivity was nearly quantitative 
(80-90%). Therefore 1% Nacholate was routinely 
used to get the high speed supernatant referred to as 
the soluble detergent extract. 
3.2.Filtration ofthesoluble/3HJCMFcholateextract 
through Sepharose 6B 
First, the applied radioactivity was totally recovered 
upon agarose chromatography. Second, only trace 
amounts of labelled material were eluted in the void 
volume of the column, indicating that the detergent 
extracted radioactivity was entirely soluble. 
Fig.2 shows that Sepharose 6B filtration resolved 
the levorphanol sensitive radioactivity into 2 major 
well-separated components: Component X (25% of 
the input radioactivity) was eluted as a fairly sharp 
and almost perfectly symmetrical peak between ferritin 
(M, 440 000; a = 61 a) and thyroglobulin (M, 669 000; 
a = 85 a). Its apparent Stokes radius (rs) was estimated 
to be 67 A (fig.2, insert), corresponding to M, - 
500 000. This value is substantially higher than that 
in [6,8]. Peak X was levorphanol-sensitive, so that 
component X is likely to represent a specific opiate 
binding macromolecule; i.e., a opiate receptor. The 
second component almost completely included in the 
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Fig. 2. Filtration through Sepharose 6B of the soluble cholate 
extract. The CMF had been labelled with [3H]etorphine in 
the absence (0) and in the presence (0) of 2 pM ievorphanol. 
(A) Blue dextran 2000; (B) thyroglobulin; (C) ferritin; (D) 
catalase; (E) aldoiase; (F) cytochrome c; (G) [ %]etorphine. 
Insert: calibration curve according to [lo]. 
gel was hardly separated from free [3H]etorphine. It 
consisted possibly of ‘low’ M, species being eluted 
slightly ahead of cytochrome c (AZ, 13 000). 
3.3. ~e~t~~g~tio~ of the soluble [3H]C3iF chalate 
extmct in sucrose density ~~d~e~ts 
In sucrose density gradients, the levorphanol-~nsi- 
tive radioactivity was resolved into two major com- 
ponents, in agreement with the agarose lution pro- 
fde (fig.3). No radioactivity was recovered in the pel- 
let. Greater than 60% of the applied counts did not 
migrate whereas the other 3040% co-sedimented with 
aldolase, aglobular, water-soluble enzyme of A4, 
158 000. This sedimentable [3H]etorphine macromol- 
ecular complex, likely to be identical to component 
X (in preparation), thus does not behave in sucrose 
gradients as one would have expected from its app. ‘S 
estimated by agarose chromatography. 
fraction number 
Fig.3. Centrifugation in sucrose density gradient of the solu- 
ble cholate extract. The CMF had been labelled with ]“Hf - 
otorphine in the absence (0) and in the presence (0) of 2 PM 
levo~~ol. (D) Catalase; (E) aldolase. The arrow indicates 
the gravity field. 
4. Discussion 
These results demonstrate clearly that a crude 
membrane fraction from the rat brain contains a mac- 
romolecular species with well defined hydrodynamic 
parameters and whose binding characteristics are those 
of an opiate receptor. Upon filtration through agarose 
(Sepharose 6B), this component elutes as would a glob- 
ular, hydrosoluble protein of M, -500 000 (app. Q 
67 A). However, in sucrose gradients, it sediments 
along with aldolase, awater-soluble enzyme of A$ 
158 OOO! This unusual hydrodynamic behavior is 
reminiscent ofthat of the cholinergic receptor protein 
solubilized from Electrophorus electricus electroplax 
[4,5] and may be accounted for by either an elongated 
shape or a low density (presence of lipids) or both. In 
this respect, the answer ests on the measurement of 
the frictional ratio and apparent specific volume of 
the [3H]etorphine macromolecular complex in crude 
cholate extracts [S 1. 
In [6,8] it was claimed that an opiate macromolec- 
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ular complex of il4, -380 000 had been solubilized 
with Brij 36T. Unfortunately, this important advance 
was not, in either study, substantiated by actual exper- 
imental results (agarose elution profiles not shown). 
However, in a similar approach and using identical 
techniques [9] no defined peak of radioactivity of 
either 380 000 or 500 OOOM, could be shown. In [9], 
in addition to ‘a broad peak of 100 000-500 000 
molecular weight,. . . . several other species of less than 
20 000 molecular weight’, was shown suggesting that 
‘a large number of distinct membrane components are 
capable of stereospecifically binding opiates in vivo’. 
We have been confronted, in the course of similar 
studies, with the following discrepancy: filtered on 
short columns (PD-10, Pharmacia) of Sephadex G-25, 
the cholateextracted radioactivity appears to be main- 
ly ‘macromolecular’ (75%in v,) whereas peak X (fig.2) 
accounts for a mere 25% of the total input! 
A trivial explanation would reside in a rapid disso- 
ciation of the macromolecular complex during chro- 
matography at cold room temperature. In fact, it is 
easy to demonstrate (in preparation) that there is no 
detectable dissociation of the complex in question (in 
the presence of a large excess of unlabelled etorphine) 
for as long as 18 h after solubilization. More likely 
then, G-25 excludes labelled components that are 
almost completely included in Sepharose 6B. Indeed, 
fig.2 reveals a levorphanol-sensitive, etorphine binding 
material slightly ahead of cytochrome c (M, 13 000, 
marker F). 
Therefore, in the mammalian brain there may be 
several distinct membrane components that bind opi- 
ates specifically. These components, which need not 
be as numerous as suggested in [9],may differ in their 
hydrodynamic properties, chemical nature and phar- 
macological specificity. Were this true it would open 
a new avenue of research in the field. 
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